The company has been given three poster slots at the Society for Immunotherapy of Cancer (SITC) next month that will focus on clinical trials of its promising single-strain live biotherapeutic, MRx0518.
The first poster will describe initial immune modulation and safety data from the neoadjuvant monotherapy trial in patients awaiting surgery for solid tumours. A neoadjuvant is a drug given as a first step to shrink a tumour before surgery.
Two further posters will provide details of MRx0518 in combination with an existing cancer drug called Keytruda. They were used to treat people who did not respond to immune checkpoint inhibitors.
One poster will provide an additional update on safety and clinical efficacy in patients from the concluded Part A of the study. The other will give information on the ongoing cohort expansion phase of the trial, Part B.
"For the first time, we will be reporting initial immune modulation and safety data from 4D pharma's study of the MRx0518 as a neoadjuvant monotherapy,” 4D’s chief scientific officer, Dr Alex Stevenson said in a statement.
“This data could be particularly important in developing our understanding of the mechanism of action of MRx0518 in the clinical setting, a key component of maximising its potential as a novel immuno-oncology therapeutic.
“In addition, having reported initial proof-of-concept for the MRx0518 and Keytruda combination study earlier this year, SITC provides the ideal platform to provide an update on progress with this study," he added.
The 35th SITC annual meeting will take place from November 9-14, 2020. The 4D posters can be found in the virtual poster hall from November 11 onwards.
For more information click here.